The Efficacy and Safety of Ibogaine Treatment for Substance Use Disorders - A Narrative Review
DOI:
https://doi.org/10.12775/QS.2026.54.69942Keywords
ibogaine, substance use disorders, opioid dependence, cocaine dependence, alcohol dependence, addiction treatmentAbstract
Introduction and aim of the study. Substance use disorders, including opioid, cocaine, and alcohol dependence, represent a significant global health challenge with high relapse rates despite existing treatments. Ibogaine, a naturally occurring indole alkaloid derived from Tabernanthe iboga, has attracted increasing scientific interest due to its reported ability to reduce withdrawal symptoms and cravings. Our study aims to evaluate the efficacy and safety of ibogaine in the treatment of substance use disorders and to determine its therapeutic potential.
Materials and methods. The paper is based on an analysis of studies available in databases such as PubMed, Google Scholar, and other scientific databases. Observational studies, retrospective surveys, controlled trials, and review papers on the use of ibogaine in the context of opioid, cocaine, and alcohol dependence were used.
Conclusions. Ibogaine, due to its modulation of serotonergic, dopaminergic, and glutamatergic neurotransmitter systems, shows promising potential in the treatment of substance use disorders. However, serious safety concerns exist, particularly cardiotoxicity manifesting as QT prolongation and potentially fatal arrhythmias. It is advisable to conduct further large-scale randomized controlled trials aimed at a more thorough evaluation of the efficacy and safety of ibogaine in the treatment of addiction.
References
1. Alper KR, et al. Fatalities Temporally Associated with the Ingestion of Ibogaine. Journal of Forensic Sciences. 2012;57(2):398-412. https://doi.org/10.1111/j.1556-4029.2011.02008.x
2. LAPPA. Ibogaine. Legislative Analysis and Public Policy Association. 2025. https://legislativeanalysis.org/wp-content/uploads/2025/04/Ibogaine.pdf
3. Mosca A, et al. Ibogaine/Noribogaine in the Treatment of Substance Use Disorders: A Systematic Review. Current Neuropharmacology. 2023;21(11):2224-2236. https://doi.org/10.2174/1570159X21666221017085612
4. Pope HG. Tabernanthe iboga: An African Narcotic Plant of Social Importance. Economic Botany. 1969;23(2):174-184. https://doi.org/10.1007/BF02860623
5. Köck P, et al. A Systematic Literature Review of Clinical Trials and Therapeutic Applications of Ibogaine. Journal of Substance Abuse Treatment. 2022;138:108717. https://doi.org/10.1016/j.jsat.2021.108717
6. Mash DC, et al. Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence. Frontiers in Pharmacology. 2018;9:529. https://doi.org/10.3389/fphar.2018.00529
7. Jacobs MT, et al. Ibogaine, a Noncompetitive Inhibitor of Serotonin Transport, Acts by Stabilizing the Cytoplasm-facing State of the Transporter. Journal of Biological Chemistry. 2007;282(40):29441-29447. https://doi.org/10.1074/jbc.M704456200
8. Wells GB, et al. Binding of Ibogaine to Rat Brain Membranes. Brain Research Bulletin. 1999;48(4):403-409. https://doi.org/10.1016/S0361-9230(99)00053-2
9. Brackenridge P. Ibogaine: A Novel Anti-Addictive Compound. Drugs and Alcohol Today. 2010;10(4):37-44. https://doi.org/10.5042/daat.2010.0724
10. Heink A, et al. A Clinical and Pharmacological Assessment of Ibogaine and Its Metabolites. Frontiers in Pharmacology. 2025;16:1744383. https://doi.org/10.3389/fphar.2025.1744383
11. Kauer JA, Malenka RC. Synaptic Plasticity and Addiction. Nature Reviews Neuroscience. 2007;8(11):844-858. https://doi.org/10.1038/nrn2234
12. Renew Health. How Ibogaine Works in the Brain to Support Healing and Change. Renew Health. 2025. https://renewhealth.com/how-ibogaine-works-in-the-brain-to-support-healing-and-change/
13. Haber SN. Neuroanatomy of Reward: A View from the Ventral Striatum. In: Gottfried JA, ed. Neurobiology of Sensation and Reward. CRC Press/Taylor & Francis. 2011. https://www.ncbi.nlm.nih.gov/books/NBK92777/
14. Volkow ND, et al. Dopamine in Drug Abuse and Addiction: Results of Imaging Studies and Treatment Implications. Archives of Neurology. 2007;64(11):1575-1579. https://doi.org/10.1001/archneur.64.11.1575
15. Popik P, et al. Inhibition of Reinforcing Effects of Morphine and Motivational Aspects of Naloxone-Precipitated Opioid Withdrawal by N-Methyl-D-Aspartate Receptor Antagonist, Memantine. Journal of Pharmacology and Experimental Therapeutics. 1995;280(2):854-865.
16. Davis AK, Barsuglia JP, Windham-Herman AM, Lynch M, Polanco M. Subjective Effectiveness of Ibogaine Treatment for Problematic Opioid Consumption: Short- and Long-Term Outcomes and Current Psychological Functioning. Journal of Psychedelic Studies. 2017;1(2):65-73. https://doi.org/10.1556/2054.01.2017.009
17. Brown TK, Alper K. Treatment of Opioid Use Disorder with Ibogaine: Detoxification and Drug Use Outcomes. The American Journal of Drug and Alcohol Abuse. 2018;44(1):24-36. https://doi.org/10.1080/00952990.2017.1320802
18. Noller GE, Frampton CM, Yazar-Klosinski B. Ibogaine Treatment Outcomes for Opioid Dependence from a Twelve-Month Follow-Up Observational Study. The American Journal of Drug and Alcohol Abuse. 2018;44(1):37-46. https://doi.org/10.1080/00952990.2017.1310218
19. Schenberg EE, et al. Treating Drug Dependence with the Aid of Ibogaine: A Retrospective Study. Journal of Psychopharmacology. 2014;28(11):993-1000. https://doi.org/10.1177/0269881114552713
20. Weiss RD, et al. Adjunctive Counseling During Brief and Extended Buprenorphine-Naloxone Treatment for Prescription Opioid Dependence: A 2-Phase Randomized Controlled Trial. Archives of General Psychiatry. 2011;68(12):1238-1246. https://doi.org/10.1001/archgenpsychiatry.2011.121
21. Larco K, Elie C, Reynolds D. The efficacy of ibogaine use in opioid use disorder compared to buprenorphine [Presentation]. UC Davis Health. https://health.ucdavis.edu/nursing/news/Events/PDF/Other_presentations/The%20efficacy%20of%20ibogaine%20use%20in%20opioid%20use%20disorder%20compared%20to%20buprenorphine.pdf
22. Schwartz EKC, et al. Cocaine Use Disorder (CUD): Current Clinical Perspectives. Substance Abuse and Rehabilitation. 2022;13:25-46. https://doi.org/10.2147/SAR.S337338
23. Wagner FA, Anthony JC. From First Drug Use to Drug Dependence: Developmental Periods of Risk for Dependence upon Cannabis, Cocaine, and Alcohol. Neuropsychopharmacology. 2002;26(4):479-488. https://doi.org/10.1016/S0893-133X(01)00367-0
24. Mu P, et al. Exposure to Cocaine Dynamically Regulates the Intrinsic Membrane Excitability of Nucleus Accumbens Neurons. Biological Psychiatry. 2011;69(10):919-927. https://doi.org/10.1016/j.biopsych.2010.09.014
25. Alburges ME, et al. Ibogaine and Cocaine Abuse: Effects on Striatal Dynorphin and Serotonin Transporter Binding Sites. Brain Research. 1999;847(1):139-142. https://doi.org/10.1016/s0006-8993(99)02017-x
26. Litjens RPW, Brunt TM. How Toxic is Ibogaine? Clinical Toxicology. 2016;54(4):297-302. https://doi.org/10.3109/15563650.2016.1138226
27. Prior PL, Prior SL. Ibogaine Effect on Cocaine Craving and Use in Dependent Patients - A Double-Blind, Placebo-Controlled Pilot Study. Jacobs Journal of Addiction Therapy. 2014;1(1):3.
28. Leite M. The Case of Brazil: After Ayahuasca, Ibogaine Opens Up Opportunity for First-Class Research in the Global South. MAPS Bulletin. 2021;31(2). https://maps.org/news/bulletin/the-case-of-brazil-after-ayahuasca-ibogaine-opens-up-opportunity-for-first-class-research-in-the-global-south/
29. He DY, Ron D. Autoregulation of Glial Cell Line-Derived Neurotrophic Factor Expression: Implications for the Long-Lasting Actions of the Anti-Addiction Drug, Ibogaine. FASEB Journal. 2006;20(13):2420-2422. https://doi.org/10.1096/fj.06-6394fje
30. Bailey CP, et al. Chronic ethanol administration alters activity in ventral tegmental area neurons after cessation of withdrawal hyperexcitability. Brain Research. 1998;803(1-2):144-52. https://doi.org/10.1016/s0006-8993(98)00654-4
31. Bailey CP, et al. Alterations in mesolimbic dopamine function during the abstinence period following chronic ethanol consumption. Neuropharmacology. 2001;41(8):989-99. https://doi.org/10.1016/s0028-3908(01)00146-0
32. Yang F, et al. GDNF Acutely Modulates Excitability and A-Type K+ Channels in Midbrain Dopaminergic Neurons. Nature Neuroscience. 2001;4(11):1071-1078. https://doi.org/10.1038/nn734
33. Kranzler HR, Soyka M. Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review. JAMA. 2018;320(8):815-824. https://doi.org/10.1001/jama.2018.11406
34. Alper KR, et al. Treatment of Acute Opioid Withdrawal with Ibogaine. The American Journal on Addictions. 1999;8(3):234-242. https://doi.org/10.1080/105504999305848
35. Koenig X, Hilber K. The Anti-Addiction Drug Ibogaine and the Heart: A Delicate Relation. Molecules. 2015;20(2):2208-2228. https://doi.org/10.3390/molecules20022208
36. Asua I. Growing Menace of Ibogaine Toxicity. British Journal of Anaesthesia. 2013;111(6):1029-1030. https://doi.org/10.1093/bja/aet339
37. O'Hearn E, Molliver ME. The olivocerebellar projection mediates ibogaine-induced degeneration of Purkinje cells: a model of indirect, trans-synaptic excitotoxicity. J Neurosci. 1997;23:1227. https://doi.org/10.1523/JNEUROSCI.17-22-08828.1997
38. Mash DC, et al. Identification of a Primary Metabolite of Ibogaine that Targets Serotonin Transporters and Elevates Serotonin. Life Sci. 1995;57(3):PL45-50. https://doi.org/10.1016/0024-3205(95)00273-9
39. Jalal S, Daher E, Hilu R. A Case of Death Due to Ibogaine Use for Heroin Addiction: Case Report. The American Journal on Addictions. 2013;22(3):302. https://doi.org/10.1111/j.1521-0391.2013.00330.x
40. Hoelen DW, Spiering W, Valk GD. Long-QT Syndrome Induced by the Antiaddiction Drug Ibogaine. New England Journal of Medicine. 2009;360(3):308-309. https://doi.org/10.1056/nejmc0804248
41. O'Connell CW, et al. Internet-Purchased Ibogaine Toxicity Confirmed with Serum, Urine, and Product Content Levels. The American Journal of Emergency Medicine. 2015;33(7):985.e5-e6. https://doi.org/10.1016/j.ajem.2014.12.023
42. Paling FP, et al. Life-Threatening Complications of Ibogaine: Three Case Reports. Netherlands Journal of Medicine. 2012;70(9):422-424. https://pubmed.ncbi.nlm.nih.gov/23123541/
43. Vlaanderen L, et al. Cardiac Arrest After Ibogaine Ingestion. Clinical Toxicology. 2014;52(6):642-643. https://doi.org/10.3109/15563650.2014.927477
44. Luz M, Mash DC. Evaluating the Toxicity and Therapeutic Potential of Ibogaine in the Treatment of Chronic Opioid Abuse. Expert Opinion on Drug Metabolism & Toxicology. 2021;17(9):1019-1032. https://doi.org/10.1080/17425255.2021.1944099
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Milena Majchrzyk, Weronika Walendziak, Magdalena Ostaszewska, Damian Zienkiewicz, Gabriela Makulec, Karolina Domosud, Natalia Mordal; Kacper Ściebura; Wiktoria Wiśniewska, Anna Malczyk
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 164
Number of citations: 0
